Regulation of hepatic steroid receptors and enzymes by the 3β-hydroxysteroid dehydrogenase inhibitor trilostane

The results show that the tissue endocrine environment is affected by trilostane treatment in the absence of sustained changes in circulating corticosteroid. The combination of increased 11β-HSD2 and reduced GR expression in target organs could be expected to ameliorate the effects of excess glucocorticoid, suggesting new therapeutic approaches.